Janumet™ (MK-0431A) combines two OADs with complementary mechanisms of action to improve glycemic control, sitagliptin and metformin. The tablet was designed in order to be bioequivalent to ...

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...

New data presented at the American Diabetes Association 70 th Annual Scientific Sessions WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) ...

There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by ...

Forbes contributors publish independent expert analyses and insights. I'm a medical journalist covering cardiology news. The FDA has approved a fixed-dose combination tablet consisting of sitagliptin ...

Glenmark Pharmaceuticals Ltd on Thursday launched sitagliptin and its fixed dose combinations (FDCs) indicated for adults with type-2 diabetes in India under SITAZIT brand and its variants. The ...

Bethesda, MD - The US Food and Drug Administration has approved the first drug combination to be used in the treatment of diabetes and elevated LDL-cholesterol levels [1]. Known as Juvisync (Merck), ...

Please provide your email address to receive an email when new articles are posted on . Similar efficacy and safety was found between once-weekly omarigliptin and once-daily sitagliptin among patients ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions from a study comparing ...

Glenmark Pharmaceuticals Ltd on Thursday launched sitagliptin and its fixed dose combinations (FDCs) indicated for adults with type-2 diabetes in India under SITAZIT brand and its variants. The ...